# Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

> **NCT02206607** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 39 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** PF-04937319 IR MST
- **DRUG:** PF-04937319 MR 1
- **DRUG:** PF-04937319 MR 2
- **DRUG:** PF-04937319 MR 3

## Key facts

- **NCT ID:** NCT02206607
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206607, "Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02206607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*